Intercell falls as vaccine halted

Patient enrolment into a clinical trial of Austrian biotech firm Intercell’s vaccine against MRSA, a superbug that is a leading cause of hospital-acquired infection, has been put on hold, sending its shares tumbling. Investors interpreted the development as a major setback for the key experimental product and shares in the Austrian biotech group lost more than a fifth of their value yesterday.